Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.60 |
| ▸ | PTAFR | P25105 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506649 | 0.84 | IDO1 (0.62) | IDO1LMNASMN1; SMN2MAPTHTT | |
| SCHEMBL29357760 | 0.82 | CYP3A4 (0.69) | CYP3A4PTAFRNAMPTFAAHALDH1A1 | |
| SCHEMBL4603002 | 0.82 | CYP3A4 (0.69) | CYP3A4PTAFRNAMPTFAAHALDH1A1 | |
| SCHEMBL25123221 | 0.82 | CYP17A1 (0.47) | CYP3A4IDO1LMNASMN1; SMN2PPARA | |
| SCHEMBL6523383 | 0.81 | KMT2A (0.62) | CYP3A4NAMPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL479925 | 0.81 | CYP3A4 (0.72) | CYP3A4NAMPTLMNAALDH1A1MAPT | |
| SCHEMBL23748572 | 0.81 | PTAFR (0.54) | CYP3A4PTAFRNAMPTRAB9ALMNA | |
| SCHEMBL11823014 | 0.81 | CYP3A4 (0.56) | CYP3A4NAMPTFAAHRAB9ALMNA | |
| SCHEMBL27507343 | 0.81 | CYP3A4 (0.71) | CYP3A4PTAFRNAMPT | |
| SCHEMBL25028453 | 0.81 | KMT2A (0.60) | CYP3A4NAMPTRAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332036-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | CYP3A4 2789/4885PTAFR 3879/4885NAMPT 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.